IB Enters Agreement with MedImageMetric

Imaging Biometrics Limited

(the "Company")

Imaging Biometrics Enters Agreement with MedImageMetric to Commercialize QSM Technology

September 16, 2025 - Imaging Biometrics, LLC (IB), a leading provider of advanced MRI analytics, is pleased to announce an agreement with MedImageMetric, LLC (MIM) to commercialize its patented quantitative susceptibility mapping (QSM) software, QSMetric™. QSMetric is available for immediate sale through IB as an annual license subscription.

QSMetric, an FDA-cleared MRI technique, measures how tissue responds to magnetic fields, revealing subtle biochemical changes often missed by conventional imaging. It enables clinicians to quantify changes in magnetic susceptibility, offering critical insights into iron deposition, microbleeds, demyelination, calcification, and other markers of disease progression or treatment response. The automated software has clinical applications across neurodegenerative diseases, multiple sclerosis, neurological and psychiatric disorders, cerebrovascular disease, traumatic brain injury, brain tumours, and more-providing the sensitivity and specificity needed for confident diagnosis.

"This agreement brings together MIM's innovation and IB's commercialization strength to accelerate access to a powerful, clinically validated imaging solution," said Dr. Yi Wang, PhD, MIM's President. "The fact that QSMetric is both FDA-cleared and patent-protected underscores its scientific rigor and commercial readiness."

The collaboration also opens the door to joint development initiatives, including:

· Integration of QSMetric with IB's solutions to enhance neuro characterization.

· Expansion into multi-parametric imaging workflows for neuro-oncology, neurodegeneration, and vascular disorders.

· Co-development of AI-driven analytics and clinical decision support tools leveraging QSMetric data.

A recent study published in Radiology demonstrated how QSM measures iron-related pathology, supporting its role in managing neurodegenerative diseases, particularly in predicting cognitive decline (Radiology, Sept 9, 2025). As demand for advanced imaging in Alzheimer's care accelerates, QSMetric is well-placed to address a US diagnostics market worth over $3.5 billion. With the rise of FDA-approved anti-amyloid therapies, MRI-based monitoring for amyloid-related imaging abnormalities (ARIA) has become a clinical and regulatory priority. QSMetric's ability to detect and quantify microhemorrhages and iron accumulation independent of imaging parameters (Radiology, Jan 1, 2012) offers a robust quantitative solution for ARIA-H surveillance-making it a valuable tool for memory clinics, imaging networks, and trial sponsors navigating this rapidly expanding market.

"QSMetric is a perfect complement to our portfolio of advanced imaging solutions," added Michael Schmainda, IB's CEO. "We're excited to bring this technology to market and help clinicians unlock deeper insights into brain pathology with greater precision and efficiency."

The Directors of the Company accept responsibility for the contents of this announcement.

-ENDS-

For further information, please contact:

Imaging Biometric Limited

Trevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda

Tel: 020 7469 0930

Peterhouse Capital Limited (Broker)

Tel: 020 7220 9797

About Imaging Biometrics® LLC: IB is a wholly owned subsidiary of Imaging Biometrics Limited, (LON: IBAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at ww.imagingbiometrics.com. Follow IB on X, @ImgBiometrics.

About MedImageMetric LLC: MIM is founded on technical and clinical research development of imaging-based biomarkers. Based on rigorous biophysics and computation, MIM has developed quantitative imaging biomarkers of tissue function and metabolism for precision diagnosis and treatment.